Moreover, we presented evidence that ATP5F1C is a prognostic biomarker of tumor recurrence and distant metastasis, as well as a marker of treatment failure in ER(+) patients undergoing Tamoxifen therapy. This evidence concerns the gene ATP5F1C and neoplasm.